Austin, United States, June 25, 2026 (GLOBE NEWSWIRE) -- According to SNS Insider, The Vaccine Adjuvants Market size was valued at USD 4.00 Billion in 2025 and is projected to reach USD 6.19 Billion by 2035, growing at a CAGR of 4.47% during 2026–2035. Rising adoption of mRNA vaccines, recombinant protein vaccines, cancer vaccines, and advanced immunization platforms has driven the demand for vaccine adjuvants.
Get a Sample Copy of the Vaccine Adjuvants Market Report 2026–2035 @ https://www.snsinsider.com/sample-request/6989
mRNA Vaccines and Advanced Immunization Platforms Drive Vaccine Adjuvants Market Growth
The growing adoption of advanced vaccine technologies is emerging as one of the most significant drivers for the vaccine adjuvants market. Pharmaceutical and biotechnology companies are increasingly developing mRNA, recombinant protein, and viral vector vaccines that require highly efficient adjuvant systems to maximize immunogenicity while reducing antigen dosage requirements. Modern adjuvant technologies enable stronger immune activation, improved durability of protection, and enhanced vaccine efficacy across a wide range of disease indications.
Leading Market Players Listed in this Report are:
- CSL Limited
- GlaxoSmithKline plc
- Novavax, Inc.
- Dynavax Technologies Corporation
- Agenus, Inc.
- Adjuvance Technologies, Inc.
- InvivoGen
- Phibro Animal Health Corporation
- Brenntag Biosector
- SPI Pharma
- SEPPIC
- Croda International plc
- OZ Biosciences
- Aurorium
- Hawaii Biotech Inc.
- Sanofi
- Merck & Co., Inc.
- Pfizer Inc.
- Johnson & Johnson
- 3M Health Care
Segmentation Analysis
By Type
The Particulate Adjuvants segment dominated the Vaccine Adjuvants Market in 2025, accounting for the largest share of total market revenue attributed to the widespread use of aluminum salts, emulsions, liposomes, and nanoparticle-based adjuvants that effectively enhance antigen presentation and generate durable immune responses. The Combination Adjuvants segment is expected to register the fastest growth during the forecast period as the demand for broader and more potent immune responses is encouraging vaccine developers to utilize multiple immunostimulatory mechanisms within a single formulation.
By Administration
The Intramuscular segment held the largest market share in 2025 due to extensive utilization across routine immunization programs, infectious disease vaccines, protein-based vaccines, and mRNA vaccine platforms. The Intradermal segment is projected to witness the fastest growth throughout the forecast period owing to the ability to achieve strong immune responses with lower antigen doses globally.
By Application
The Infectious Diseases segment dominated the market in 2025 due to large-scale immunization programs targeting influenza, COVID-19, hepatitis, HPV, pneumococcal diseases, and other infectious conditions continue to generate substantial demand for adjuvant-enhanced vaccines. The Cancer segment is expected to be the fastest-growing application during the forecast period owing to the growing investments in cancer immunotherapy, personalized vaccines, neoantigen-based therapies, and therapeutic oncology vaccines globally.
Regional Insights
North America dominated the global Vaccine Adjuvants Market in 2025. The region benefits from advanced biopharmaceutical research infrastructure, strong government support for vaccine innovation, extensive immunization programs, and the presence of leading pharmaceutical and biotechnology companies actively developing next-generation vaccine platforms.
The U.S. Vaccine Adjuvants Market was valued at approximately USD 0.62 Billion in 2025 and is expected to reach approximately USD 1.61 Billion by 2035, growing at a CAGR of 9.05%. The U.S. continues to lead the market due to significant investments from organizations such as NIH, BARDA, CDC, and FDA, strong vaccine R&D activities, expanding oncology vaccine development, and widespread adoption of advanced adjuvant technologies across mRNA, recombinant protein, and viral vector vaccines.
The Europe Vaccine Adjuvants Market is estimated to be USD 1.08 Billion in 2025 and is projected to reach USD 1.67 Billion by 2035, growing at a CAGR of 4.47% during 2026–2035. Europe accounted for a significant share of the global market in 2025. Strong regulatory oversight from the European Medicines Agency (EMA), expanding biotechnology research capabilities, and increasing investment in pandemic preparedness programs continue to support regional growth. Germany, France, and the United Kingdom remain key contributors to vaccine innovation and commercialization activities.
The Asia-Pacific region is projected to be the fastest-growing market throughout the forecast period. Rapid expansion of vaccine manufacturing capacity, increasing immunization coverage, rising infectious disease burden, and growing government investments in biotechnology and healthcare infrastructure across China, India, Japan, South Korea, and Southeast Asia are driving substantial market growth.
Purchase the Vaccine Adjuvants Market Report to Access Competitive Benchmarking, Vaccine Pipeline Analysis, Adjuvant Technology Trends, Market Share Insights, and Strategic Forecasts Through 2035 @ https://www.snsinsider.com/checkout/6989
Recent Developments:
- 2026: GSK expanded next-generation adjuvant optimization programs focused on enhancing AS01 and AS03 platforms for mRNA and protein subunit vaccines, improving antigen dose-sparing capabilities and strengthening T-cell mediated immune responses.
- 2026: Novavax advanced commercialization of its Matrix-M adjuvant through expanded global licensing partnerships, increasing adoption across influenza vaccines and pandemic preparedness programs while demonstrating improved durability of antibody responses.
Exclusive Sections of the Report (The USPs)
- NEXT-GENERATION ADJUVANT TECHNOLOGY ANALYSIS – helps you understand developments across nanoparticle, liposomal, emulsion-based, and combination adjuvant platforms driving future vaccine innovation.
- VACCINE PIPELINE & IMMUNIZATION PROGRAM TRACKER – helps you evaluate global vaccine development trends, immunization initiatives, pandemic preparedness programs, and commercial opportunities.
- mRNA, RECOMBINANT & ADVANCED VACCINE PLATFORM INSIGHTS – helps you identify growth opportunities associated with emerging vaccine technologies and their evolving adjuvant requirements.
- ONCOLOGY VACCINE & IMMUNOTHERAPY OPPORTUNITY ASSESSMENT – helps you assess advancements in therapeutic cancer vaccines, neoantigen platforms, personalized medicine, and immune modulation strategies.
- GLOBAL REGULATORY & COMMERCIALIZATION BENCHMARKS – helps you uncover regulatory trends, approval pathways, manufacturing scalability, and market access strategies across major regions.
- FUTURE VACCINE INNOVATION & PANDEMIC PREPAREDNESS OUTLOOK – helps you gauge developments in next-generation immunization technologies, rapid-response vaccine platforms, and long-term vaccine market opportunities through 2035.
Vaccine Adjuvants Market Report Scope
| Report Attributes | Details |
| Market Size in 2025 | USD 4.00 Billion |
| Market Size by 2035 | USD 6.19 Billion |
| CAGR | CAGR of 4.47% From 2026 to 2035 |
| Base Year | 2025 |
| Forecast Period | 2026-2035 |
| Historical Data | 2022-2024 |
| Key Segments | • By Type (Adjuvant emulsion, Pathogen, Combination, Particulate, and Others) • By Administration (Oral, Intramuscular, Intradermal, Intranasal, and Others) • By Application (Cancer, Infectious diseases, and Others) |
| Regional Analysis/Coverage | North America (US, Canada), Europe (Germany, UK, France, Italy, Spain, Russia, Poland, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN Countries, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Mexico, Colombia, Rest of Latin America). |
Related Market Reports
Veterinary Vaccine Adjuvants Market Size & Growth, 2026
Vaccine Technologies Market Trends & Outlook, 2026
Human Vaccines Market Size & Share, 2026
Vaccine Market Growth & Analysis, 2026
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
